Regeneron Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Regeneron Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-12-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-12-31 | 2004-09-30 | 2004-06-30 | 2004-03-31 | 2003-12-31 | 2003-09-30 | 2003-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| statements of operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenues: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net product sales | 1,631,000,000 | 1,415,600,000 | 2,002,900,000 | 1,946,400,000 | 1,918,600,000 | 1,761,300,000 | 1,851,800,000 | 1,786,100,000 | 1,772,100,000 | 1,668,000,000 | 1,699,300,000 | 1,801,400,000 | 1,754,400,000 | 1,638,600,000 | 3,975,200,000 | 2,279,900,000 | 4,137,800,000 | 1,724,300,000 | 1,621,800,000 | 1,482,200,000 | 1,226,900,000 | 1,236,700,000 | 1,286,400,000 | 1,238,300,000 | 1,205,300,000 | 1,104,400,000 | 1,096,421,000 | 1,025,488,000 | 996,382,000 | 987,909,000 | 978,718,000 | 957,367,000 | 924,133,000 | 858,245,000 | 862,521,000 | 857,468,000 | 834,219,000 | 784,182,000 | 749,524,000 | 737,562,000 | 657,819,000 | 544,573,000 | 521,518,000 | 448,844,000 | 418,022,000 | 362,378,000 | 406,088,000 | 367,118,000 | 333,893,000 | 318,740,000 | 281,471,000 | 249,172,000 | 199,519,000 | 127,931,000 | 5,468,000 | 5,039,000 | 4,427,000 | 5,269,000 | 4,936,000 | 5,197,000 | 9,852,000 | 3,543,000 | 2,706,000 | |||||||||||||||||||||
| yoy | -14.99% | -19.63% | 8.16% | 8.97% | 8.27% | 5.59% | 8.97% | -0.85% | 1.01% | 1.79% | -57.25% | -20.99% | -57.60% | -4.97% | 145.11% | 53.82% | 237.26% | 39.43% | 26.07% | 19.70% | 1.79% | 11.98% | 17.33% | 20.75% | 20.97% | 11.79% | 12.03% | 7.12% | 7.82% | 15.11% | 13.47% | 11.65% | 10.78% | 9.44% | 15.08% | 16.26% | 26.82% | 44.00% | 43.72% | 64.32% | 57.36% | 50.28% | 28.42% | 22.26% | 25.20% | 13.69% | 44.27% | 47.34% | 67.35% | 149.15% | 5047.60% | 4844.87% | 4406.87% | 2327.99% | 10.78% | -3.04% | -55.06% | 39.32% | 92.05% | |||||||||||||||||||||||||
| qoq | 15.22% | -29.32% | 2.90% | 1.45% | 8.93% | -4.89% | 3.68% | 0.79% | 6.24% | -1.84% | -5.67% | 2.68% | 7.07% | -58.78% | 74.36% | -44.90% | 139.97% | 6.32% | 9.42% | 20.81% | -0.79% | -3.86% | 3.88% | 2.74% | 9.14% | 0.73% | 6.92% | 2.92% | 0.86% | 0.94% | 2.23% | 3.60% | 7.68% | -0.50% | 0.59% | 2.79% | 6.38% | 4.62% | 1.62% | 12.12% | 20.80% | 4.42% | 16.19% | 7.37% | 15.36% | -10.76% | 10.62% | 9.95% | 4.75% | 13.24% | 12.96% | 24.89% | 55.96% | 2239.63% | 8.51% | 13.82% | -15.98% | 6.75% | -5.02% | -47.25% | 30.93% | |||||||||||||||||||||||
| collaboration revenue | 1,860,700,000 | 1,531,200,000 | 1,606,900,000 | 1,660,100,000 | 1,524,000,000 | 1,266,800,000 | 1,370,000,000 | 1,438,300,000 | 1,316,700,000 | 1,378,100,000 | 831,675,000 | 1,050,600,000 | 1,043,600,000 | 1,232,500,000 | 695,750,000 | 1,073,900,000 | 954,700,000 | 754,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other revenue | 183,900,000 | 81,900,000 | 179,400,000 | 114,200,000 | 104,500,000 | 116,900,000 | 212,500,000 | 138,300,000 | 69,300,000 | 116,000,000 | 127,700,000 | 84,200,000 | 59,200,000 | 94,000,000 | 86,200,000 | 99,000,000 | 46,000,000 | 50,000,000 | 123,400,000 | 158,600,000 | 211,800,000 | 63,200,000 | 135,200,000 | 103,100,000 | 90,300,000 | 84,800,000 | 102,248,000 | 117,370,000 | 111,024,000 | 86,158,000 | 107,073,000 | 61,506,000 | 113,500,000 | 56,440,000 | 51,657,000 | 26,964,000 | 23,100,000 | 17,381,000 | 787,000 | 1,074,000 | 1,223,000 | 851,000 | ||||||||||||||||||||||||||||||||||||||||||
| expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 1,421,700,000 | 1,327,400,000 | 1,412,100,000 | 1,271,500,000 | 1,200,000,000 | 1,248,400,000 | 1,177,200,000 | 1,075,300,000 | 1,085,300,000 | 1,101,200,000 | 1,043,100,000 | 911,300,000 | 794,300,000 | 843,800,000 | 785,600,000 | 665,400,000 | 714,200,000 | 742,900,000 | 744,500,000 | 684,600,000 | 722,000,000 | 583,900,000 | 683,100,000 | 663,400,000 | 1,048,300,000 | 641,800,000 | 601,253,000 | 556,972,000 | 529,289,000 | 498,586,000 | 527,983,000 | 529,749,000 | 509,975,000 | 507,435,000 | 479,206,000 | 543,047,000 | 559,930,000 | 470,112,000 | 461,210,000 | 425,924,000 | 390,330,000 | 343,113,000 | 351,745,000 | 337,728,000 | 294,501,000 | 287,379,000 | 268,140,000 | 224,045,000 | 187,463,000 | 180,299,000 | 181,024,000 | 158,295,000 | 147,373,000 | 138,862,000 | 127,924,000 | 143,149,000 | 129,392,000 | 125,212,000 | 122,043,000 | 124,526,000 | 117,471,000 | 76,314,000 | 73,855,000 | 66,577,000 | 61,270,000 | 51,689,000 | 43,864,000 | 41,235,000 | 35,774,000 | 34,808,000 | 34,398,000 | 32,084,000 | 37,911,000 | 41,116,000 | 40,642,000 | 35,912,000 | 34,789,000 | 32,828,000 | 36,297,000 | 32,181,000 | 33,267,000 | 34,650,000 | 33,717,000 | |
| acquired in-process research and development | 10,000,000 | 12,300,000 | 13,800,000 | 56,200,000 | 23,900,000 | 7,100,000 | 30,000,000 | 100,000,000 | 56,100,000 | 30,000,000 | 197,000,000 | 28,100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| selling, general, and administrative | 634,200,000 | 633,000,000 | 792,200,000 | 714,400,000 | 758,800,000 | 689,000,000 | 737,700,000 | 640,500,000 | 652,000,000 | 601,100,000 | 660,500,000 | 529,100,000 | 476,300,000 | 450,000,000 | 559,600,000 | 445,000,000 | 414,700,000 | 405,600,000 | 303,500,000 | 326,900,000 | 348,300,000 | 367,300,000 | 586,800,000 | 419,900,000 | 417,300,000 | 410,800,000 | 491,314,000 | 369,232,000 | 364,884,000 | 330,770,000 | 409,913,000 | 306,766,000 | 306,908,000 | 296,846,000 | 325,937,000 | 270,045,000 | 292,038,000 | 289,677,000 | 294,954,000 | 209,993,000 | 174,588,000 | 158,991,000 | 143,743,000 | 149,748,000 | 102,414,000 | 108,850,000 | 82,085,000 | 97,607,000 | 72,463,000 | 77,260,000 | 57,739,000 | 46,883,000 | 47,705,000 | 58,428,000 | 32,916,000 | 24,585,000 | 23,411,000 | 20,641,000 | 15,658,000 | 14,679,000 | 14,005,000 | 13,491,000 | 11,368,000 | 13,465,000 | 11,024,000 | |||||||||||||||||||
| cost of goods sold | 275,600,000 | 265,500,000 | 326,800,000 | 262,300,000 | 257,800,000 | 240,400,000 | 306,800,000 | 224,500,000 | 192,400,000 | 208,400,000 | 302,200,000 | 141,300,000 | 149,200,000 | 207,300,000 | 811,700,000 | 238,800,000 | 539,400,000 | 183,200,000 | 179,600,000 | 131,000,000 | 102,500,000 | 78,800,000 | 108,500,000 | 115,900,000 | 67,000,000 | 70,900,000 | 43,990,000 | 30,817,000 | 35,950,000 | 69,243,000 | 52,733,000 | 46,388,000 | 42,133,000 | 61,253,000 | 44,534,000 | 29,901,000 | 41,247,000 | 78,942,000 | 71,078,000 | 67,199,000 | 60,855,000 | 42,570,000 | 37,957,000 | 33,655,000 | 29,945,000 | 27,473,000 | 34,491,000 | 28,253,000 | 27,283,000 | 29,055,000 | 30,169,000 | 20,145,000 | 21,843,000 | 12,298,000 | 450,000 | 395,000 | 382,000 | 599,000 | 372,000 | 405,000 | 717,000 | 631,000 | 292,000 | |||||||||||||||||||||
| cost of collaboration and contract manufacturing | 254,600,000 | 198,800,000 | 238,600,000 | 228,800,000 | 222,400,000 | 193,400,000 | 210,200,000 | 211,900,000 | 212,500,000 | 249,100,000 | 238,400,000 | 176,500,000 | 147,900,000 | 197,600,000 | 170,900,000 | 214,400,000 | 154,300,000 | 124,800,000 | 173,500,000 | 143,000,000 | 173,000,000 | 138,500,000 | 115,400,000 | 110,700,000 | 85,500,000 | 108,300,000 | 73,182,000 | 79,552,000 | 55,711,000 | 45,655,000 | 53,007,000 | 57,844,000 | 60,788,000 | 22,915,000 | 30,147,000 | 14,327,000 | 27,786,000 | 32,810,000 | 39,753,000 | 41,884,000 | 27,985,000 | 41,385,000 | ||||||||||||||||||||||||||||||||||||||||||
| other operating income | 15,500,000 | 8,000,000 | 14,600,000 | 15,300,000 | -500,000 | -500,000 | -600,000 | -500,000 | -6,600,000 | -45,700,000 | -17,400,000 | -20,200,000 | -15,800,000 | 42,000,000 | -31,300,000 | -40,500,000 | -145,200,000 | -44,600,000 | -50,200,000 | -40,400,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from operations | 1,079,500,000 | 591,700,000 | 990,200,000 | 1,179,500,000 | 1,069,600,000 | 751,400,000 | 972,900,000 | 1,111,000,000 | 1,016,500,000 | 946,700,000 | 1,146,800,000 | 1,223,700,000 | 1,109,900,000 | 1,258,500,000 | 2,639,700,000 | 1,847,200,000 | 3,347,200,000 | 1,112,700,000 | 1,167,000,000 | 1,053,100,000 | 656,400,000 | 700,100,000 | 675,700,000 | 738,500,000 | 315,600,000 | 480,000,000 | 718,058,000 | 626,923,000 | 622,188,000 | 567,231,000 | 538,811,000 | 559,926,000 | 550,312,000 | 430,542,000 | 347,003,000 | 362,802,000 | 291,628,000 | 329,308,000 | 231,082,000 | 392,422,000 | 344,859,000 | 283,553,000 | 247,367,000 | 182,719,000 | 222,406,000 | 185,939,000 | 212,073,000 | 236,802,000 | 158,103,000 | 153,050,000 | 145,670,000 | 202,364,000 | 87,478,000 | 22,201,000 | -58,457,000 | -60,319,000 | -40,981,000 | -12,777,000 | -32,094,000 | -23,724,000 | -28,659,000 | -34,599,000 | -19,931,000 | -19,389,000 | -15,911,000 | -38,667,000 | -30,604,000 | -33,649,000 | -33,486,000 | -28,257,000 | -24,249,000 | -21,663,000 | -29,527,000 | -34,387,000 | -32,167,000 | -28,340,000 | 3,974,000 | -9,479,000 | -12,643,000 | 23,794,000 | -17,139,000 | -25,703,000 | -26,932,000 | |
| yoy | 0.93% | -21.25% | 1.78% | 6.17% | 5.22% | -20.63% | -15.16% | -9.21% | -8.42% | -24.78% | -56.56% | -33.75% | -66.84% | 13.10% | 126.20% | 75.41% | 409.93% | 58.93% | 72.71% | 42.60% | 107.98% | 45.85% | -5.90% | 17.80% | -49.28% | -15.38% | 33.27% | 11.97% | 13.06% | 31.75% | 55.28% | 54.33% | 88.70% | 30.74% | 50.16% | -7.55% | -15.44% | 16.14% | -6.58% | 114.77% | 55.06% | 52.50% | 16.64% | -22.84% | 40.67% | 21.49% | 45.58% | 17.02% | 80.73% | 589.38% | -349.19% | -435.49% | -313.46% | -273.76% | 82.14% | 154.25% | 43.00% | -7.24% | 19.03% | 47.81% | -10.52% | -34.87% | -42.38% | -52.48% | 36.84% | 26.21% | 55.33% | 13.41% | -17.83% | -24.62% | -23.56% | -843.00% | 262.77% | 154.43% | -219.11% | -123.19% | -63.12% | -53.06% | ||||||
| qoq | 82.44% | -40.24% | -16.05% | 10.27% | 42.35% | -22.77% | -12.43% | 9.30% | 7.37% | -17.45% | -6.28% | 10.25% | -11.81% | -52.32% | 42.90% | -44.81% | 200.82% | -4.65% | 10.82% | 60.44% | -6.24% | 3.61% | -8.50% | 134.00% | -34.25% | -33.15% | 14.54% | 0.76% | 9.69% | 5.27% | -3.77% | 1.75% | 27.82% | 24.07% | -4.35% | 24.41% | -11.44% | 42.51% | -41.11% | 13.79% | 21.62% | 14.63% | 35.38% | -17.84% | 19.61% | -12.32% | -10.44% | 49.78% | 3.30% | 5.07% | -28.02% | 131.33% | 294.03% | -137.98% | -3.09% | 47.19% | 220.74% | -60.19% | 35.28% | -17.22% | 73.59% | 2.80% | 21.86% | -58.85% | 26.35% | -9.05% | 0.49% | 18.51% | 16.53% | 11.94% | -26.63% | -14.13% | 6.90% | 13.50% | -813.14% | -141.92% | -25.03% | -153.14% | -238.83% | -33.32% | -4.56% | |||
| operating margin % | 66.19% | 41.80% | 49.44% | 60.60% | 55.75% | 42.66% | 52.54% | 62.20% | 57.36% | 56.76% | 67.49% | 67.93% | 63.26% | 76.80% | 66.40% | 81.02% | 80.89% | 64.53% | 71.96% | 71.05% | 53.50% | 56.61% | 52.53% | 59.64% | 26.18% | 43.46% | 65.49% | 61.13% | 62.44% | 57.42% | 55.05% | 58.49% | 59.55% | 50.17% | 40.23% | 42.31% | 34.96% | 41.99% | 30.83% | 53.21% | 52.42% | 52.07% | 47.43% | 40.71% | 53.20% | 51.31% | 52.22% | 64.50% | 47.35% | 48.02% | 51.75% | 81.21% | 43.84% | 17.35% | -1069.07% | -1197.04% | -925.71% | -242.49% | -650.20% | -456.49% | -290.90% | -976.55% | -736.55% | |||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income | 442,800,000 | 322,000,000 | -21,600,000 | 327,300,000 | 573,300,000 | -34,600,000 | 193,000,000 | 17,600,000 | 85,300,000 | -70,700,000 | 195,300,000 | 301,400,000 | -133,600,000 | -183,800,000 | -122,200,000 | -16,400,000 | 420,000,000 | 154,900,000 | 72,400,000 | -28,500,000 | 272,200,000 | -25,400,000 | 220,800,000 | 37,800,000 | -82,900,000 | 73,800,000 | -34,542,000 | 16,432,000 | 40,804,000 | 24,606,000 | 21,991,000 | 11,861,000 | -19,061,000 | 9,248,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense | -3,600,000 | -8,700,000 | -10,500,000 | -13,800,000 | -14,800,000 | -16,100,000 | -18,300,000 | -17,800,000 | -18,900,000 | -18,000,000 | -17,400,000 | -15,300,000 | -13,100,000 | -13,600,000 | -14,100,000 | -14,200,000 | -14,400,000 | -14,600,000 | -14,800,000 | -26,300,000 | -9,700,000 | -6,100,000 | -6,700,000 | -7,800,000 | -8,000,000 | -7,700,000 | -7,349,000 | -7,494,000 | -6,918,000 | -6,439,000 | -6,035,000 | -6,182,000 | -5,401,000 | -7,501,000 | -3,609,000 | -1,715,000 | -2,748,000 | -6,169,000 | -6,350,000 | -9,232,000 | -10,177,000 | -11,613,000 | -11,661,000 | -11,736,000 | -11,365,000 | -11,675,000 | -11,495,000 | -11,413,000 | -11,236,000 | -11,160,000 | -4,061,000 | -4,047,000 | -3,719,000 | -2,458,000 | -2,234,000 | -2,342,000 | -2,084,000 | -295,000 | -1,772,000 | -2,674,000 | -3,011,000 | -3,011,000 | -3,011,000 | -3,011,000 | -3,010,000 | -3,011,000 | -3,011,000 | -3,011,000 | -3,011,000 | -3,011,000 | -3,011,000 | -3,013,000 | -3,014,000 | -3,014,000 | -3,011,000 | -3,136,000 | -3,106,000 | -2,982,000 | -2,905,000 | |||||
| income before income taxes | 1,518,700,000 | 905,000,000 | 958,100,000 | 1,493,000,000 | 1,628,100,000 | 700,700,000 | 1,147,600,000 | 1,110,800,000 | 1,082,900,000 | 858,000,000 | 1,324,700,000 | 1,509,800,000 | 963,200,000 | 1,061,100,000 | 2,503,400,000 | 1,816,600,000 | 3,752,800,000 | 1,253,000,000 | 1,224,600,000 | 998,300,000 | 918,900,000 | 668,600,000 | 889,800,000 | 768,500,000 | 224,700,000 | 546,100,000 | 676,167,000 | 635,861,000 | 656,074,000 | 585,398,000 | 554,767,000 | 565,605,000 | 525,850,000 | 432,289,000 | 341,527,000 | 365,881,000 | 292,256,000 | 330,151,000 | 227,289,000 | 393,289,000 | 327,996,000 | 276,523,000 | 221,287,000 | 176,078,000 | 203,119,000 | 175,263,000 | 198,153,000 | 225,684,000 | 147,692,000 | 141,831,000 | 134,559,000 | 191,468,000 | ||||||||||||||||||||||||||||||||
| income tax expense | 127,100,000 | 40,400,000 | 152,400,000 | 195,800,000 | -12,000,000 | 103,000,000 | 114,500,000 | 40,200,000 | 127,600,000 | 194,100,000 | 111,100,000 | 87,600,000 | 274,400,000 | 184,400,000 | 653,900,000 | 137,800,000 | 75,400,000 | 156,200,000 | 21,600,000 | 44,000,000 | -97,800,000 | -98,900,000 | -31,600,000 | -85,000,000 | 144,186,000 | -41,206,000 | -104,662,000 | -107,418,000 | -381,248,000 | -177,288,000 | -138,106,000 | -183,358,000 | -88,412,000 | -101,077,000 | -96,038,000 | -164,415,000 | -72,295,000 | -182,891,000 | -133,353,000 | -200,502,000 | -79,140,500 | -96,358,000 | -110,384,000 | -109,820,000 | -46,912,750 | -84,378,000 | -60,316,000 | -42,957,000 | 218,000 | -728,000 | 3,079,000 | |||||||||||||||||||||||||||||||||
| net income | 1,391,600,000 | 808,700,000 | 917,700,000 | 1,340,600,000 | 1,432,300,000 | 722,000,000 | 1,159,600,000 | 1,007,800,000 | 968,400,000 | 817,800,000 | 1,197,100,000 | 1,315,700,000 | 852,100,000 | 973,500,000 | 2,229,000,000 | 1,632,200,000 | 3,098,900,000 | 1,115,200,000 | 1,149,200,000 | 842,100,000 | 897,300,000 | 624,600,000 | 792,000,000 | 669,600,000 | 193,100,000 | 461,100,000 | 820,353,000 | 594,655,000 | 551,412,000 | 477,980,000 | 173,519,000 | 388,317,000 | 387,744,000 | 248,931,000 | 253,115,000 | 264,804,000 | 196,218,000 | 165,736,000 | 154,994,000 | 210,398,000 | 194,643,000 | 76,021,000 | 110,176,000 | 79,720,000 | 92,735,000 | 65,443,000 | 96,806,000 | 141,306,000 | 87,376,000 | 98,874,000 | 470,407,000 | 191,468,000 | 76,743,000 | 11,651,000 | -62,365,000 | -62,505,000 | -43,447,000 | -14,597,000 | -33,875,000 | -25,474,000 | -30,522,000 | -31,518,000 | -21,115,000 | -18,459,000 | -11,618,000 | -35,838,000 | -26,774,000 | -29,917,000 | -30,971,000 | -27,410,000 | -23,576,000 | -20,380,000 | -29,672,000 | -34,652,000 | 26,999,000 | -4,123,000 | 2,792,000 | -11,076,000 | -14,549,000 | 64,532,000 | -19,377,000 | -27,400,000 | -28,736,000 | |
| yoy | -2.84% | 12.01% | -20.86% | 33.02% | 47.90% | -11.71% | -3.13% | -23.40% | 13.65% | -15.99% | -46.29% | -19.39% | -72.50% | -12.71% | 93.96% | 93.82% | 245.36% | 78.55% | 45.10% | 25.76% | 364.68% | 35.46% | -3.46% | 12.60% | -64.98% | -3.53% | 372.77% | 53.14% | 42.21% | 92.01% | -31.45% | 46.64% | 97.61% | 50.20% | 63.31% | 25.86% | 0.81% | 118.01% | 40.68% | 163.92% | 109.89% | 16.16% | 13.81% | -43.58% | 6.13% | -33.81% | -79.42% | -26.20% | 13.86% | 748.63% | -854.28% | -406.32% | -276.64% | -179.82% | 84.10% | 145.37% | 42.35% | 7.48% | 20.64% | 65.35% | -12.05% | -21.14% | -38.30% | -62.49% | 30.75% | 13.56% | 46.80% | 4.38% | -20.90% | -187.32% | 394.30% | -1162.75% | 212.86% | -285.57% | -106.39% | -114.41% | -59.58% | -49.37% | ||||||
| qoq | 72.08% | -11.88% | -31.55% | -6.40% | 98.38% | -37.74% | 15.06% | 4.07% | 18.42% | -31.68% | -9.01% | 54.41% | -12.47% | -56.33% | 36.56% | -47.33% | 177.88% | -2.96% | 36.47% | -6.15% | 43.66% | -21.14% | 18.28% | 246.76% | -58.12% | -43.79% | 37.95% | 7.84% | 15.36% | 175.46% | -55.32% | 0.15% | 55.76% | -1.65% | -4.41% | 34.95% | 18.39% | 6.93% | -26.33% | 8.09% | 156.04% | -31.00% | 38.20% | -14.03% | 41.70% | -32.40% | -31.49% | 61.72% | -11.63% | -78.98% | 145.68% | 149.49% | 558.68% | -118.68% | -0.22% | 43.86% | 197.64% | -56.91% | 32.98% | -16.54% | 49.27% | 14.39% | 58.88% | -67.58% | 33.85% | -10.51% | -3.40% | 12.99% | 16.26% | 15.68% | -31.32% | -14.37% | -228.35% | -754.84% | -247.67% | -125.21% | -23.87% | -122.55% | -433.03% | -29.28% | -4.65% | |||
| net income margin % | 85.32% | 57.13% | 45.82% | 68.88% | 74.65% | 40.99% | 62.62% | 56.42% | 54.65% | 49.03% | 70.45% | 73.04% | 48.57% | 59.41% | 56.07% | 71.59% | 74.89% | 64.68% | 70.86% | 56.81% | 73.14% | 50.51% | 61.57% | 54.07% | 16.02% | 41.75% | 74.82% | 57.99% | 55.34% | 48.38% | 17.73% | 40.56% | 41.96% | 29.00% | 29.35% | 30.88% | 23.52% | 21.13% | 20.68% | 28.53% | 29.59% | 13.96% | 21.13% | 17.76% | 22.18% | 18.06% | 23.84% | 38.49% | 26.17% | 31.02% | 167.12% | 76.84% | 38.46% | 9.11% | -1140.54% | -1240.42% | -981.41% | -277.04% | -686.28% | -490.17% | -309.81% | -889.59% | -780.30% | |||||||||||||||||||||
| net income per share | 13.24 | 7.58 | 8.54 | 12.4 | 13.25 | 6.7 | 10.89 | 9.48 | 9.05 | 7.64 | 11.21 | 12.31 | 7.9 | 9.12 | 20.98 | 15.37 | 29.51 | 10.58 | 10.82 | 7.98 | 8.19 | 5.69 | 7.26 | 6.12 | 1.77 | 4.23 | 7.59 | 5.5 | 5.12 | 4.44 | 1.61 | 3.64 | 3.66 | 2.36 | 2.41 | 2.53 | 1.88 | 1.59 | 1.49 | 2.04 | 1.89 | 0.74 | 1.09 | 0.79 | 0.92 | 0.66 | 0.97 | 1.44 | 0.89 | 1.02 | 4.95 | 2.02 | 0.81 | 0.12 | -0.68 | -0.69 | -0.49 | -0.275 | -0.41 | -0.31 | -0.38 | -0.4 | -0.27 | -0.23 | -0.15 | -0.33 | -0.52 | -0.58 | ||||||||||||||||
| weighted-average shares outstanding - basic | 105.1 | 106.7 | 107.9 | 108.1 | 108.1 | 107.8 | 106.7 | 106.3 | 107 | 107.1 | 107.1 | 106.9 | 107.9 | 106.8 | 105.7 | 106.2 | 105 | 105.4 | 107.6 | 105.5 | 109.6 | 109.8 | 109.2 | 109.4 | 109.2 | 108.9 | 107.9 | 108,033 | 107,800 | 107,648 | 106,338 | 106,706 | 106,034 | 105,572 | 104,719 | 104,833 | 104,633 | 104,290 | 103,061 | 103,348 | 102,886 | 102,227 | 100,612 | 100,796 | 100,391 | 98,709 | 97,917 | 98,226 | 97,700 | 96,878 | 94,685 | 95,012 | 94,589 | 93,446 | ||||||||||||||||||||||||||||||
| weighted-average shares outstanding - diluted | 108.6 | 111.2 | 115.1 | 116.2 | 115.4 | 115.1 | 113.7 | 113.4 | 113.9 | 114 | 113.5 | 112.8 | 114 | 113.1 | 112.2 | 113.9 | 110.8 | 110.5 | 115.1 | 113.9 | 117.9 | 115.1 | 114.6 | 114.2 | 114.6 | 115.5 | 114.8 | 115,088 | 114,477 | 114,906 | 115,954 | 117,028 | 116,137 | 115,106 | 116,367 | 116,466 | 116,231 | 114,228 | 115,230 | 115,944 | 115,259 | 114,519 | 113,413 | 117,423 | 113,032 | 112,151 | 111,290 | 116,713 | 111,060 | 109,369 | 115,382 | 115,830 | 110,167 | 107,734 | ||||||||||||||||||||||||||||||
| statements of comprehensive income | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive income, net of tax: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on debt securities | 22.1 | 38.1 | -66 | 128.2 | 7.9 | 3.5 | 95.4 | 21.3 | -15.7 | 57.2 | -35.9 | -6.4 | -0.8 | -1.8 | -4.9 | 44.6 | -28.8 | 7.875 | 1 | 14.4 | 16.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on foreign currency translation | 1.3 | -1.1 | 0.375 | 1.9 | 0.2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| comprehensive income | 1,415 | 845.7 | 849.6 | 1,470.7 | 1,439.6 | 725.7 | 1,255.5 | 1,028.7 | 952.3 | 875 | 1,233.4 | 1,264.4 | 798.4 | 829.6 | 2,193.3 | 1,626 | 3,098.4 | 1,102.1 | 1,147.7 | 837.4 | 941.9 | 594.4 | 796.6 | 670.3 | 206.1 | 476.2 | -1,617,042.9 | 595,748 | 555,394 | 468,339 | 150,324 | 409,804 | 395,976 | 255,887 | 243,174 | 256,701 | 197,058 | 161,528 | 155,845 | 198,966 | 165,892 | 71,674 | 135,532 | 102,352 | 95,533 | 68,096 | 98,469 | 141,884 | 85,591 | 98,396 | 471,145 | 191,935 | 75,709 | 12,176 | ||||||||||||||||||||||||||||||
| the accompanying notes are an integral part of the financial statements. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | 96,300,000 | 562,000 | -863,000 | -216,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on foreign currency translation | -0.6 | 0.5 | -0.4 | -0.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax (benefit) expense | -21,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on cash flow hedges | 1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.3 | 0.2 | 0.2 | -0.3 | -1.4 | -1 | -2,387.3 | 341 | 608 | 1,439 | 735 | 2 | 28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized loss on debt securities | -62.475 | -51.3 | -53.7 | -144.9 | -13.3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| sanofi collaboration revenue | 317,100,000 | 353,300,000 | 269,100,000 | 246,900,000 | 427,100,000 | 404,200,000 | 349,100,000 | 246,400,000 | 427,592,000 | 256,265,000 | 237,753,000 | 189,490,000 | 199,523,000 | 245,175,000 | 222,128,000 | 210,367,000 | 131,165,000 | 144,392,000 | 163,414,000 | 219,694,000 | 165,672,000 | 224,735,000 | 195,110,000 | 173,356,000 | 135,271,000 | 132,925,000 | 142,595,000 | 130,508,000 | 110,950,000 | 134,359,000 | 85,529,000 | 99,273,000 | 104,779,000 | 145,042,000 | 88,988,000 | 85,005,000 | 79,802,000 | 84,446,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| bayer collaboration revenue | 360,600,000 | 299,900,000 | 244,200,000 | 281,400,000 | 320,800,000 | 302,800,000 | 289,000,000 | 276,200,000 | 301,536,000 | 264,373,000 | 262,863,000 | 247,928,000 | 297,133,000 | 236,625,000 | 210,355,000 | 193,939,000 | 181,484,000 | 191,298,000 | 191,896,000 | 179,592,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized loss on cash flow hedges | -1.4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on marketable securities | 6,947 | 752 | 3,374 | -11,080 | -23,930 | 21,485 | 8,204 | 2,653 | -421.25 | 578 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive income: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on marketable securities, net of tax | 6,956 | 840 | 851 | -11,432 | -28,751 | -4,347 | 25,356 | 22,632 | 2,798 | -478 | 738 | 467 | -1,034 | 525 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investment income | 2,087,750 | 3,301,000 | 2,801,000 | 2,249,000 | 1,677,000 | 937,000 | -2,259,000 | 618,000 | 954,000 | 456,000 | 384,000 | 517,000 | 501,000 | 610,000 | 715,000 | 998,000 | 1,037,000 | 638,000 | 453,000 | 592,000 | 439,000 | 2,648,000 | 3,674,000 | 4,535,000 | 7,304,000 | 5,840,000 | 6,841,000 | 6,743,000 | 5,525,000 | 3,858,000 | 3,684,000 | 3,481,000 | 2,866,000 | 2,746,000 | 2,539,000 | 2,230,000 | 1,832,000 | 1,417,000 | 1,105,000 | 1,124,000 | 868,000 | 1,285,000 | 1,101,000 | |||||||||||||||||||||||||||||||||||||||||
| interest and other income | -950,250 | -222,000 | -2,173,000 | -1,406,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized loss on marketable securities, net of tax | -2,867.75 | -8,103 | -4,208 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| bayer healthcare collaboration revenue | 164,809,000 | 157,596,000 | 134,237,000 | 123,846,000 | 137,095,000 | 135,853,000 | 97,295,000 | 125,312,000 | 85,695,000 | 88,583,000 | 31,104,000 | 14,907,000 | 21,791,000 | 26,701,000 | 9,124,000 | 12,483,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| technology licensing and other revenue | 14,204,250 | 17,529,000 | 11,451,000 | 27,837,000 | 8,445,000 | 8,166,000 | 7,788,000 | 7,542,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investment and other income | 1,750,000 | 2,603,000 | 1,849,000 | 81,000 | 2,952,000 | 2,591,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on extinguishment of debt | -1,934,000 | -21,000 | -15,964,000 | -942,000 | -22,682,000 | -10,787,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of collaboration manufacturing | 21,517,000 | 21,938,000 | 16,434,000 | 16,099,000 | 13,623,000 | 10,320,000 | 12,330,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| technology licensing | 4,419,750 | 5,893,000 | 5,893,000 | 5,893,000 | 5,892,000 | 5,893,000 | 5,893,000 | 5,893,000 | 5,893,000 | 5,228,000 | 7,845,000 | 10,038,000 | 10,037,000 | 10,037,000 | 10,038,000 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | 6,278,000 | 2,143,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive loss: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| unrealized loss on marketable securities | -1,785 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| condensed statements of operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| contract research and other | 669,000 | 879,000 | 875,000 | 477,000 | 1,576,000 | 1,974,000 | 2,122,000 | 1,321,000 | 1,662,000 | 2,076,000 | 1,886,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| condensed statements of comprehensive income | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income before income tax benefit | 76,743,000 | 11,651,000 | -61,803,000 | -63,368,000 | -43,663,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenues | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other collaboration revenue | 10,094,000 | 11,123,000 | 12,481,000 | 10,120,750 | 13,761,000 | 13,635,000 | 13,087,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average shares outstanding, basic and diluted | 91,046 | 90,436 | 89,162 | 81,638 | 81,492 | 81,169 | 78,937 | 78,689 | 78,493 | 66,069 | 65,950 | 65,563 | 57,011 | 56,915 | 56,727 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| sanofi-aventis collaboration revenue | 85,329,000 | 57,298,750 | 75,583,000 | 84,941,000 | 68,671,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income before income tax expense | -30,304,000 | -12,028,250 | -18,036,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| contract research and development from sanofi-aventis | 29,086,500 | 42,006,000 | 38,606,000 | 35,734,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other contract research and development | 8,392,000 | 10,872,000 | 12,047,000 | 10,649,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on early extinguishment of debt | -7,000 | -931,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| contract research and development | 12,311,000 | 15,917,000 | 13,645,000 | 10,110,000 | 11,448,000 | 14,991,000 | 14,587,000 | 13,867,000 | 11,533,000 | 13,545,000 | 13,502,000 | 18,780,000 | 25,621,000 | 27,146,000 | 41,610,000 | 19,121,000 | 10,882,000 | 9,774,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| contract manufacturing | 236,000 | 4,176,000 | 4,267,000 | 3,632,000 | 3,557,000 | 4,661,000 | 2,821,000 | 2,707,000 | 3,310,000 | 10,898,000 | 1,272,000 | 2,610,000 | 2,151,000 | 6,510,000 | 758,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 9,289,000 | 8,935,000 | 8,202,000 | 7,628,000 | 6,019,000 | 6,299,000 | 5,946,000 | 6,895,000 | 6,219,000 | 6,216,000 | 6,146,000 | 4,853,000 | 4,184,000 | 4,235,000 | 3,790,000 | 4,237,000 | 3,601,000 | 3,488,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income before cumulative effect of a change in accounting principle | -35,838,000 | -26,774,000 | -29,917,000 | -30,971,000 | -27,410,000 | -23,576,000 | -21,193,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cumulative effect of adopting statement of financial accounting standards no. 123r | 813,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cumulative effect of adopting sfas 123r | -0.01 | 0.01 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other contract income | 5,640,000 | 25,000,000 | 42,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research progress payments | 25,000,000 | 17,770,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per share | 13.24 | 7.58 | 8.54 | 12.4 | 13.25 | 6.7 | 10.89 | 9.48 | 9.05 | 7.64 | 11.21 | 12.31 | 7.9 | 9.12 | 20.98 | 15.37 | 29.51 | 10.58 | 10.82 | 7.98 | 8.19 | 5.69 | 7.26 | 6.12 | 1.77 | 4.23 | 7.59 | 5.5 | 5.12 | 4.44 | 1.61 | 3.64 | 3.66 | 2.36 | 2.41 | 2.53 | 1.88 | 1.59 | 1.49 | 2.04 | 1.89 | 0.74 | 1.09 | 0.79 | 0.92 | 0.66 | 0.97 | 1.44 | 0.89 | 1.02 | 4.95 | 2.02 | 0.81 | 0.12 | -0.68 | -0.69 | -0.49 | -0.275 | -0.41 | -0.31 | -0.38 | -0.4 | -0.27 | -0.23 | -0.15 | -0.33 | -0.52 | -0.58 | ||||||||||||||||
| basic | -0.295 | -0.62 | 0.48 | -0.07 | 0.05 | -0.2 | -0.26 | 1.17 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | -0.295 | -0.62 | 0.48 | -0.07 | 0.05 | -0.2 | -0.26 | 1.06 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average shares outstanding: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic | 57,970 | 55,978 | 55,917 | 55,815 | 55,468 | 55,383 | 55,283 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted | 57,970 | 55,978 | 55,917 | 55,815 | 55,468 | 55,383 | 63,620 |
We provide you with 20 years income statements for Regeneron Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Regeneron Pharmaceuticals stock. Explore the full financial landscape of Regeneron Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Regeneron Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.